Chu SC - Search Results

1

Neratinib + capecitabine sustains health-related quality of life in patients with HER2-positive metastatic breast cancer and ≥ 2 prior HER2-directed regimens.

Moy B, Oliveira M, Saura C, Gradishar W, Kim SB, Brufsky A, Hurvitz SA, Ryvo L, Fagnani D, Kalmadi S, Silverman P, Delaloge S, Alarcon J, Kwong A, Lee KS, Ang PCS, Ow SGW, Chu SC, Bryce R, Keyvanjah K, Bebchuk J, Zhang B, Oestreicher N, Bose R, Chan N. Moy B, et al. Among authors: chu sc. Breast Cancer Res Treat. 2021 Jul;188(2):449-458. doi: 10.1007/s10549-021-06217-4. Epub 2021 Apr 28. Breast Cancer Res Treat. 2021. PMID: 33909203 Free PMC article. Clinical Trial.

2

Analysis of the pan-Asian subgroup of patients in the NALA Trial: a randomized phase III NALA Trial comparing neratinib+capecitabine (N+C) vs lapatinib+capecitabine (L+C) in patients with HER2+metastatic breast cancer (mBC) previously treated with two or more HER2-directed regimens.

Dai MS, Feng YH, Chen SW, Masuda N, Yau T, Chen ST, Lu YS, Yap YS, Ang PCS, Chu SC, Kwong A, Lee KS, Ow S, Kim SB, Lin J, Chung HC, Ngan R, Kok VC, Rau KM, Sangai T, Ng TY, Tseng LM, Bryce R, Bebchuk J, Chen MC, Hou MF. Dai MS, et al. Among authors: chu sc. Breast Cancer Res Treat. 2021 Oct;189(3):665-676. doi: 10.1007/s10549-021-06313-5. Epub 2021 Sep 23. Breast Cancer Res Treat. 2021. PMID: 34553296 Free PMC article. Clinical Trial.

3

Antiestrogen use in breast cancer patients reduces the risk of subsequent lung cancer: A population-based study.

Chu SC, Hsieh CJ, Wang TF, Hong MK, Chu TY. Chu SC, et al. Among authors: chu ty. Cancer Epidemiol. 2017 Jun;48:22-28. doi: 10.1016/j.canep.2017.02.010. Epub 2017 Mar 17. Cancer Epidemiol. 2017. PMID: 28319725

4

Hematologic Markers as Prognostic Factors in Nonmetastatic Esophageal Cancer Patients under Concurrent Chemoradiotherapy.

Wu YF, Chu SC, Chang BS, Cheng YT, Wang TF. Wu YF, et al. Among authors: chu sc. Biomed Res Int. 2019 Jan 29;2019:1263050. doi: 10.1155/2019/1263050. eCollection 2019. Biomed Res Int. 2019. PMID: 30834254 Free PMC article.

5

Insuline-Like Growth Factor-2 (IGF2) and Hepatocyte Growth Factor (HGF) Promote Lymphomagenesis in p53-null Mice in Tissue-specific and Estrogen-signaling Dependent Manners.

Huang HS, Chu SC, Chen PC, Lee MH, Huang CY, Chou HM, Chu TY. Huang HS, et al. Among authors: chu ty, chu sc. J Cancer. 2021 Aug 21;12(20):6021-6030. doi: 10.7150/jca.60120. eCollection 2021. J Cancer. 2021. PMID: 34539876 Free PMC article.

6

Presence of pleural effusion is associated with a poor prognosis in patients with epidermal growth factor receptor-mutated lung cancer receiving tyrosine kinase inhibitors as first-line treatment.

Wang TF, Chu SC, Lee JJ, Yang GG, Huang WH, Chang ET, Low T, Wu YF, Kao RH, Lin CB. Wang TF, et al. Among authors: chu sc. Asia Pac J Clin Oncol. 2017 Aug;13(4):304-313. doi: 10.1111/ajco.12658. Epub 2017 Jan 26. Asia Pac J Clin Oncol. 2017. PMID: 28124437

7

Younger tamoxifen-treated breast cancer patients also had higher risk of endometrial cancer and the risk could be reduced by sequenced aromatase inhibitor use: A population-based study in Taiwan.

Chu SC, Hsieh CJ, Wang TF, Hong MK, Chu TY. Chu SC, et al. Among authors: chu ty. Tzu Chi Med J. 2019 Jul 23;32(2):175-180. doi: 10.4103/tcmj.tcmj_17_19. eCollection 2020 Apr-Jun. Tzu Chi Med J. 2019. PMID: 32269951 Free PMC article.

8

A phase II study of weekly paclitaxel and epirubicin in recurrent or refractory squamous cell carcinoma of the head and neck.

Wang TF, Chu SC, Kao RH, Yao CY, Li CC. Wang TF, et al. Among authors: chu sc. Jpn J Clin Oncol. 2008 Jul;38(7):459-63. doi: 10.1093/jjco/hyn052. Epub 2008 Jun 26. Jpn J Clin Oncol. 2008. PMID: 18586668 Clinical Trial.

9

Effectiveness of Chinese Herbal Medicine as a Complementary Treatment for Neutropenia Prevention and Immunity Modulation During Chemotherapy in Patients With Breast Cancer: Protocol for a Real-World Pragmatic Clinical Trial.

Wang KH, Shen HS, Chu SC, Wang TF, Lin CW, Huang WH, Wu YF, Ho CC, Pang CY, Li CC. Wang KH, et al. Among authors: chu sc. JMIR Res Protoc. 2024 Mar 11;13:e55662. doi: 10.2196/55662. JMIR Res Protoc. 2024. PMID: 38466979 Free PMC article.

10

Lymphocyte percentage and platelet count correlate with the treatment outcome to tyrosine kinase inhibitors in epidermal growth factor receptor-mutated lung adenocarcinoma.

Li CC, Lin CB, Chu SC, Huang WH, Lee JJ, Yang GG, Wang TF, Wu YF. Li CC, et al. Among authors: chu sc. Medicine (Baltimore). 2020 Jul 17;99(29):e21275. doi: 10.1097/MD.0000000000021275. Medicine (Baltimore). 2020. PMID: 32702917 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

292 results

Search Page

Filters